Following Cathie Wood: Aggressively adding over 500,000 shares of nuclear energy newcomer X-Energy, while continuing to optimize positioning in the precision medicine sector

On Thursday, July 16, all three major U.S. stock indices closed lower. The S&P 500 ended at 7,533.77 points, down 0.51%; the Nasdaq declined more notably, closing at 25,881.95 points, a drop of 1.47%; the Dow Jones Industrial Average was relatively resilient, finishing at 52,552.97 points, down 0.20%.

On the same day, Cathie Wood significantly increased her positions in nuclear energy-related stocks and continued expanding into the AI-powered autonomous driving sector, while also making nuanced adjustments to her holdings in the precision medicine space.

Buying focus: Heavy bets on clean energy and AI-driven healthcare as dual growth engines

ARK’s most notable move that day was a substantial increase in its stake in $X-Energy (XE.US)$ by 507,347 shares—a move that likely reflects Cathie Wood’s strong conviction in the nuclear energy revival trend. As a leader in fourth-generation nuclear reactor technology, X-Energy is advancing small modular reactor (SMR) solutions, which are becoming a key driver in the clean energy transition. Under global net-zero commitments, nuclear power—offering stable, zero-carbon baseload electricity—is poised for a new wave of growth opportunities.

Positioning in the precision medicine sector also deserves attention. ARK increased its holdings in $Prime Medicine (PRME.US)$ by 424,438 shares and in $COMPASS Pathways (CMPS.US)$ by 395,987 shares—the former specializes in gene-editing technologies, while the latter pioneers innovative treatments in mental health. These allocations demonstrate ARK’s deep understanding of the foundational dynamics in medtech. $Absci Corp (ABSI.US)$ It also bought 314,500 shares of a company leveraging large AI models to accelerate antibody drug design—an investment fully aligned with ARK’s thesis of deeply integrating AI with biomedicine.

Positioning in the AI-powered autonomous driving segment was even more diversified, with increased stakes in $Pony AI (PONY.US)$ 205,332 shares and $WeRide (WRD.US)$ 24,448 shares, reflecting recognition of the technological capabilities of Chinese concept autonomous driving companies. At the same time, it added 65,383 shares to further enhance its position in AI-powered logistics automation. $Kodiak AI (KDK.US)$ 65,383 shares, further strengthening its allocation in the AI logistics automation sector.

Selling activity: Precisely adjusting concentration in the healthcare sector

On the selling side, ARK significantly reduced its stake by $AtaiBeckley (ATAI.US)$ 1,123,010 shares, which may reflect a reassessment of the company's commercialization progress or portfolio risk management considerations. As a biotech firm focused on developing mental health therapeutics, Atai/Beckley faces relatively high regulatory uncertainty.

Additionally, ARK also trimmed several genomics testing-related holdings, including $Personalis (PSNL.US)$ 243,532 shares,$Illumina (ILMN.US)$ 28,117 shares, and $Natera (NTRA.US)$ 19,375 shares. This series of moves likely stems from a reallocation of structural opportunities within the precision medicine segment, illustrating Cathie Wood’s strategy of retaining strong performers while divesting weaker ones in this space.

Notably, ARK also slightly reduced its position by $Baidu (BIDU.US)$ 5,000 shares, possibly related to its selective reallocation among Chinese AI-related stocks.

Futubull’s [Opportunities Page] now features celebrity portfolio tracking! Choose from multiple celebrity holdings, follow top investors’ moves with one click, precisely target quality stocks, and invest with greater confidence!

129K Views